Compare ACADIA Pharmaceuticals Inc. (ACAD) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs HubSpot Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while HubSpot Inc trades at $199.63 (market cap $10.50B). The key difference: HubSpot Inc is far larger — about 2.3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | HUBS | |
|---|---|---|
Market Cap | $4.49B | $10.50B |
Sector | Health | Technology |
52-Week High | $28.06 | $560.90 |
52-Week Low | $20.06 | $170.39 |
Enterprise Value | $3.69B | $9.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
HUBS trades at $205.23, up 6.82% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $188 and resistance at $208. Recent earnings beats and 23% revenue growth in Q1 2026 highlight robust execution. Analyst consensus is overwhelmingly bullish with an 80.85% buy rating and a $273.53 price target, suggesting significant upside from current levels.
Outlook remains positive driven by AI integration and customer growth, but high P/E of 102.02 poses valuation risk. Competition from Salesforce and SaaS sector volatility are key concerns. Net income margin improvement to 3.04% in 2025 signals profitability traction, yet investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
